FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
632 letters match. Newest first.
-
DrugsAmWiner & Raphe Holdings, LLC dba rapheGenerics Corp
FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.
High risk -
DrugsChengdu Innovation Pharmaceutical Co., Ltd.
FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.
High risk -
DrugsWuhu Nuowei Chemistry Co., Ltd.
FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.
High risk -
DrugsStrukmyer LLC dba Strukmyer Medical
Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.
High risk -
DrugsShantou Kangjie Daily Chemical Industry Co., Ltd
FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.
High risk -
DrugsImperial Palace Commodity -Dongguan- Co., Ltd.
FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.
High risk -
DrugsCenter for Instrumental Analysis of China Pharmaceutical University
Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.
High risk -
DrugsGlobal Calcium Pvt. Limited
FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.
High risk -
DrugsFagron Compounding Services, LLC dba Fagron Sterile Service
FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.
High risk -
DrugsKardesler Ucan Yaglar Sanayi Anonim Sirketi
Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.
High risk -
DrugsSanofi
FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.
High risk -
DrugsAtlanta Supersource, Inc.
Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.
High risk -
DrugsINCELL Corporation LLC
FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.
High risk -
DrugsIndoco Remedies Limited
FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.
High risk -
DrugsBhargava Phytolab Private Limited
FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.
High risk -
DrugsViatris, Inc.
FDA warns Viatris that its Indore, India, drug plant had unreliable quality data and weak investigations.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsAkron Formulations India Private Limited
Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.
High risk -
DrugsBrands International Corporation
Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.
High risk -
DrugsMicro Orgo Chem
Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.
High risk -
DrugsDr. Brite, LLC
FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.
High risk -
DrugsGuangzhou Four E’s Scientific Co., Ltd.
FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.
High risk -
DrugsLCC Ltd.
FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.
High risk -
DrugsZhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.
FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.
High risk -
DrugsCatwalk Cosmetic Laboratories Pty Ltd.
FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.
High risk -
DrugsEurosirel S.P.A
FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.
High risk -
DrugsHangzhou Huiji Biotechnology Co., Ltd.
FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.
High risk -
DrugsOriginitalia SRL
FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.
High risk -
DrugsUnexo Lifesciences, Private Limited
FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.
High risk -
DrugsColgate-Palmolive/Tom's of Maine, Inc.
FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.
High risk -
DrugsTianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.
FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.
High risk -
DrugsZhejiang Qimei Cosmetics Co., Ltd.
Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.
High risk -
DrugsMultaler et Cie SAS
FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.
High risk -
DrugsAnalytical Food Laboratories, Inc.
FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.
High risk -
DrugsMedOffice Saglik Endustri Anonim Sirketi
FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.
High risk -
DrugsChoice All Natural, Inc. dba Om Botanical
FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.
High risk -
DrugsDiora Kimya Sanayi ve Ticaret Limited Sirketi
FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.
High risk -
DrugsSoliteint Kozmetikai KFT
Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.
High risk -
DrugsOmni Lens Pvt. Ltd.
FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.
High risk -
DrugsOutin Futures Corp.
FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.
High risk -
DrugsMMC Healthcare Ltd.
FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.
High risk -
DrugsSupercore Products Group, Inc.
FDA warns Supercore that Hard Steel and Gold Hard Steel Plus are unapproved, mislabeled drugs with hidden sildenafil; Hard Steel also has acetaminophen.
High risk -
DrugsMakra Kozmetika D.O.O.
FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.
High risk -
DrugsLittle Moon Essentials, LLC
FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.
High risk -
DrugsDiamond Chemical Co., Inc.
Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.
High risk -
DrugsClean Solutions LLC
FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.
High risk -
DrugsAzurity Pharmaceuticals, Inc.
FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.
High risk -
DrugsAccupack Midwest, Inc.
Accupack Midwest, an over-the-counter drug contract manufacturer, lacked adequate water controls and process validation.
High risk -
DrugsWittman Pharma, Inc.
FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.
High risk -
DrugsAerosol and Liquid Packaging, Inc.
FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.
High risk